Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAF1 | P04049 | 1/20 | 0.36 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.34 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.34 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.34 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.34 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.34 |
| ▸ | CNR1 | P21554 | 1/20 | 0.31 |
| ▸ | CNR2 | P34972 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | GRN | P28799 | 1/20 | 0.31 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10569844 | 0.87 | CNR1 (0.40) | CNR1CNR2KDM4ELMNA | |
| SCHEMBL10222903 | 0.83 | ALDH1A1 (0.36) | RAF1HCRTR1HCRTR2SLC6A2SLC6A4 | |
| SCHEMBL15417666 | 0.82 | LMNA (0.43) | KDM4ELMNA | |
| SCHEMBL19557879 | 0.82 | MAPK14 (0.38) | RAF1HCRTR1HCRTR2SLC6A2SLC6A4 | |
| SCHEMBL13750404 | 0.82 | SLC6A2 (0.33) | HCRTR1HCRTR2SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL21325428 | 0.82 | SLC6A2 (0.36) | HCRTR1HCRTR2SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL23052795 | 0.79 | SLC6A2 (0.32) | HCRTR1HCRTR2SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL24884359 | 0.79 | HCRTR1 (0.34) | HCRTR1HCRTR2SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL23985503 | 0.79 | SLC6A2 (0.34) | HCRTR1HCRTR2SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL22680867 | 0.79 | MPO (0.34) | RAF1HCRTR1HCRTR2SLC6A2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230242537-A1 | IMIDAZOPYRIMIDINES AS MODULATORS OF IL-17 | JANSSEN PHARMACEUTICA N.V. (BE) | 2023-08-03 | — | — | US | disclosed |
| US-20230242537-A1 | IMIDAZOPYRIMIDINES AS MODULATORS OF IL-17 | JANSSEN PHARMACEUTICA N.V. (BE) | 2023-08-03 | — | — | US | disclosed |
| US-20180093973-A1 | BIARYL INHIBITORS OF BRUTON'S TYROSINE KINASE | BIOGEN MA INC. | 2018-04-05 | — | — | US | disclosed |
| US-9809577-B2 | Biaryl inhibitors of Bruton's tyrosine kinase | BIOGEN MA INC. (US) | 2017-11-07 | — | — | US | disclosed |
| US-20160311802-A1 | BIARYL INHIBITORS OF BRUTON'S TYROSINE KINASE | BIOGEN MA INC. | 2016-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180093973-A1 | BIARYL INHIBITORS OF BRUTON'S TYROSINE KINASE | ABL1, BTK, LYN | RAF1 137/4885HCRTR1 4822/4885HCRTR2 4736/4885 |
| US-20230242537-A1 | IMIDAZOPYRIMIDINES AS MODULATORS OF IL-17 | IL17A, IL23R, IL2 | RAF1 1099/4885HCRTR1 2160/4885HCRTR2 2984/4885 |
| US-20160311802-A1 | BIARYL INHIBITORS OF BRUTON'S TYROSINE KINASE | ABL1, BTK, LYN | RAF1 137/4885HCRTR1 4822/4885HCRTR2 4736/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.